Report Overview: Our analysis includes total web visits (desktop and mobile) to U.S. and international web domains, mobile app monthly active users (MAUs), daily active users (DAUs), and total time spent (where applicable). Throughout the report, we display Y/Y changes across each of these key metr
Dorchester Minerals, L.P. Announces 2025 Results DALLAS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Dorchester Minerals, L.P. (the “Partnership”) (NASDAQ-DMLP) announced today the Partnership’s net income for the year ended December 31, 2025 of $57,352,000 or $1.16 per common unit. A comparison of the Partnership’s consolidated results for the twelve month periods ended December 31, 2025 and 2024 are set forth below: Twelve Months Ended December 31, 2025 2024Operating Revenues$152,832,000 $161,523,000Net Income$57,352,000 $92,449,000Net Income Per Common Unit$1.16 $2.13 The Partnership’s indepen...
Figure 1. 4Q25 Results vs. EstimatesSource: Company reports, Wedbush estimates, FactSet consensus4Q results ahead of expectations. Etsy reported GMS declines in 4Q of -3.8% Y/Y to $3.6B, in line with St. estimates. Total revenue of $882mm (+3.5% Y/Y) was also consistent with expectations, implying
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences SAN DIEGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that members of the management team will participate in the following upcoming investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference, Virtual. Fireside discussion, February 25, 2026, 12:40 p.m. ET.TD...
Dorchester Minerals, L.P. Announces Appointment of Manager to Board of Managers DALLAS, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Dorchester Minerals, L.P. (the “Partnership”) (NASDAQ: DMLP) announced today Mr. A. Troy Sturrock has been appointed to the board of managers of the general partner of our general partner, as an independent manager and member of the advisory committee effective February 11, 2026. Mr. Sturrock’s appointment fills the vacancy created by the death of C.W. “Bill” Russell. Mr. Sturrock has over 25 years of accounting and financial reporting experience, with a focus on the ...
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that members of the management team will participate in a fireside discussion during Guggenheim's Emerging Outlook: Biotech Summit 2026 on February 11th in New York, NY at 3:30 p.m. ET. Access to a live webcast of the event, as ...
First Busey Corporation Announces 2025 Fourth Quarter Earnings LEAWOOD, Kan., Jan. 27, 2026 (GLOBE NEWSWIRE) -- First Busey Corporation (Nasdaq: BUSE) Announces 2025 Fourth Quarter Earnings. Net Income Diluted EPS Net Interest Margin1 ROAA1 ROATCE1 $60.8 million$65.2 million (adj)2 $0.63$0.68 (adj)2 3.71%3.59% (adj)2 1.32%1.41% (adj)2 12.59%13.58% (adj)2 MESSAGE FROM OUR CHAIRMAN, PRESIDENT, & CEO Our results this quarter represent a meaningful culmination to a year of strong performance and the completed merger and integration of CrossFirst. Profitability in the fourth ...
Dorchester Minerals, L.P. Announces Its Fourth Quarter Distribution DALLAS, Jan. 22, 2026 (GLOBE NEWSWIRE) -- — Dorchester Minerals, L.P. (NASDAQ:DMLP) announced today the Partnership’s fourth quarter 2025 cash distribution. The distribution of $0.755712 per common unit represents activity for the three-month period ended December 31, 2025 and is payable on February 12, 2026 to common unitholders of record as of February 2, 2026. Cash receipts attributable to the Partnership’s Royalty Properties during the fourth quarter totaled approximately $32.2 million. Approximately 62% of these re...
Report Overview: Our analysis includes total web visits (desktop and mobile) to U.S. and international web domains, mobile app monthly active users (MAUs), daily active users (DAUs), and total time spent (where applicable). Throughout the report, we display Y/Y changes across each of these key metr
Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026 Completed enrollment in DENALI Part 2a; dose confirmation expected in 1H 2026DENALI Part 2 trial topline readout expected by year end 2026; potential to support accelerated approvalInitiation of the ASPENOVA Phase 3, randomized, confirmatory trial planned in 1H 2026 SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational f...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.